We describe the case of a 30-year-old female with no family history of psoriasis and suffering from Crohn's disease successfully treated with infliximab at the dosage of 5 mg/kg.

However, despite their documented therapeutic efficacy in both diseases, treatment with anti-TNF agents in patients with IBD can induce or worsen psoriatic skin lesions, a condition described as paradoxical psoriasis.

Nov 1, 2024 · The etiology of paradoxical psoriasis remains elusive, though dysregulation of cytokines like interferon (IFN)-α and TNF-α may be implicated. Notably, paradoxical psoriasis showcases an elevated proportion of CD123+ plasmacytoid dendritic cells and IFNα overexpression in contrast to psoriasis vulgaris.

Psoriasis, palmoplantar pustulosis and nail psoriasis had been induced immediately after one infusion through to 63 months post treatment. The underlying mechanism of induction of psoriasis/psoriasiform exanthema in these patients remains elusive ( Wollina et al 2008 ).

Scalp psoriasis with alopecia is a rare cutaneous reaction to tumor necrosis factor alpha antagonists. This reaction often reverses with discontinuation of the offending drug and initiation of topical treatments; however, irreversible hair loss may occur if a scarring alopecia develops.

Apr 1, 2011 · We report a 31-year-old woman with extensive CD and perianal lesions, without response to conventional treatment. She paradoxically developed a cutaneous eruption with psoriasiform morphology and distribution during treatment with both anti-TNF-α approved in Europe for CD, infliximab and adalimumab.

Infliximab is currently approved in adults and children over the age of 6 years for the treatment of psoriasis and psoriatic arthritis, as well as rheumatoid arthritis, ankylosing spondylitis, Crohn disease and ulcerative colitis.

Paradoxically, there have been numerous reports of new-onset psoriasis following tumor necrosis factor-α antagonist therapy in patients with IBD. Here, we report a case with Crohn's disease who developed Infliximab-induced plaque-type psoriasis 4 months after initiation of treatment with Infliximab. Figure

Inflectra (Infliximab-dyyb) for Psoriasis Overview Inflectra is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of active psoriatic arthritis and chronic severe plaque psoriasis.

Dec 16, 2024 · The baseline association of classical psoriasis (non-drug induced) with the seronegative rheumatic and gastrointestinal inflammatory diseases treated by TNF inhibitors, initially made this reaction a challenge to define and study.